Abstract
Lung cancer, the most prevalent type of cancer, would likely account for 1.8 million cancer deaths (18%) worldwide in 2020. Non-small cell lung cancer (NSCLC) is more common in clinically diagnosed patients, whereas small cell lung cancer (SCLC) is less common but typically develops more quickly. However, traditional treatment methods, such as surgery, adjuvant chemoradiotherapy, have their limitations. Antibody-drug couplings (ADCs), one of the fastest growing cancer drugs of late, use exclusive binding of their monoclonal antibodies (Mabs) to the surface antigens of cancer cells to precisely deliver anti-cancer drugs to target cancer cells. ADC, which specifically targets cancer cells while preserving healthy ones, is a promising cancer treatment. Five ADCs approved by the FDA for solid malignancies, while numerous ADCs targeting NSCLC and SCLC are globally in number of clinical trials. This article reviews the therapeutic use of ADC in non-small cell lung cancer and small cell lung cancer. Develop an understanding of the mechanisms and clinical effects of ADCs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
